Generalized Anxiety Disorder Therapeutics Market Report

Pune, Oct. 27, 2022 (GLOBE NEWSWIRE) — According to the latest report published by Growth Plus Reports, the global generalized anxiety disorder therapeutics market is expected to clock US$ 12193 million by 2030 and to grow at a CAGR of 3.6% during the forecast period. This exclusive information is published by Growth Plus Reports in its report titled “generalized anxiety disorder therapeutics Market – Global Outlook & Forecast 2022-2030”

Growth Drivers

The socioeconomic impact of mental health difficulties will continue to increase as a result of the associated loss of employment and effects on lifestyle and social involvement. Pharmaceutical companies are stepping up their efforts to hasten the commercialization of treatments for anxiety disorders and depression. This has prompted various governments to initiate initiatives aimed at decreasing the burden of mental illnesses and anxiety disorders.

The global generalized anxiety disorder therapeutics market has been analyzed from three perspectives: drug class, distribution channel, and region

Get a Sample Copy of the Research Report: https://growthplusreports.com/inquiry/request-sample/generalized-anxiety-disorder-therapeutics-market/7905

Excerpts from ‘By Drug Class Segmentation’

Based on drug class, the global generalized anxiety disorder therapeutics market is subdivided into:

• Antidepressants
• Azapirones
• Benzodiazepines
• Others

The antidepressant drugs are further subcategorized into selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors (SNRIs), and others. Due to the drug’s greater efficacy, which reduced the symptoms of anxiety and other linked mental illnesses, the antidepressants segment dominated the market for treating generalised anxiety disorder. Numerous antidepressants, including selective serotonin reuptake inhibitors, are regarded as the first line of treatment for generalised anxiety disorders since they have been shown to lessen its…